Orascom-Siemens-Arab Contractors consortium signs MoU to build high-speed rail system    Oman to close land borders again to curb coronavirus    State revenues will likely fall by EGP 150 bln in FY 2020/21 on Covid-19    Transmar succeeded in promoting trade, doubling reefer container shipping    Gut bacteria tied to Covid-19 severity    Egypt receives 19 rail carriages from Russia under mega deal    New boss Rooney backs Derby to respond after defeat by Rotherham    CBE offers EGP 16bn T-bills on Sunday    World Bank provides $200m loan to Egypt for air quality monitoring projects    Egypt detects 887 new coronavirus cases; 54 fatalities on Saturday    Live score: National Bank of Egypt v Ahly (Egyptian Premier League)    Facebook to ban ads promoting weapon accessories, protective gear in US    Explainer: Road to Palestinian vote full of obstacles    Tennis: Australian Open arrivals hit by 4 COVID-19 positive tests    US state capitals, Washington on alert for possible pro-Trump armed protests    In Photos: Egyptian archaeological mission at Saqqara Necropolis announces new major discoveries    Armin Laschet picked as new leader of Germany's CDU party    Egypt's Sisi discusses bilateral ties, regional developments with Sudanese delegation    Bank ABC acquires Blom Bank Egypt for $480 million: Sources    Egypt's Mostaqbal Watan party dominates the leading posts of parliament's 25 committees    Egypt's budget deficit to GDP ratio receded to 3.6% in first half of FY2020/21, revenues rose by 16%    Mubarak-era politician Safwat El-Sherif dies aged 88    Handball: Egypt ease past Chile 35-29 in World Championship opener    Egypt's president, Siemens CEO discuss final deal on construction of electric train system    Hollywood actor Mena Massoud visits Giza pyramids, says is proud of Egyptian culture    Egypt reopens airspace and resumes flights with Qatar    Egypt, Tunisia to establish maritime trade route    Egypt eyes gradual return for tourism after revenues fall to $4 bln in 2020    Seasoned Egyptian screenwriter Wahid Hamed dies at 76    Coronavirus strikes Egypt's youth team as 17 players, coach test positive    Nassef Sawiris plans to up his stake in owner of New York Knicks, Rangers    Cairo International Book Fair suspended for five months over coronavirus concerns    Egypt unveils largest archaeological discovery in 2020 with over 100 intact sarcophagi    Trump says won't blame Egypt for being ‘upset' over GERD dispute with Ethiopia    Egypt, Ethiopia, Sudan to resume Nile dam talks today    Global Finance: Egypt's Tarek Amer among the world's top 20 central bank governors    The Facebook Preacher's Search for Fame, and Egypt's Economy    Egypt calls on UNSC to address oil spill risks off Yemen coast    Egypt economically strong in face of COVID-19, reforms ongoing: International Cooperation Minister    Arafa Holding reports $144,000 COVID-19-related losses in April    Egypt's efforts in Libya to activate free will of Libyan people: Al-Sisi    Hyksos campaigns were internal takeover, not foreign invaders: study    COVID-19 affects Egypt sporting clubs    COVID-19 will soon turn to seasonal like swine flu: Presidential Health Advisor    ‘Egypt's Support' coalition convenes to discuss its Senate election list    Robbery attempt leads to discovery of Ptolemaic monuments in Qena    Flouting international guidance, Ethiopia unilaterally starts filling its Nile dam    Zaha speaks out after online racial abuse    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.





Exclusive: New global lab network will compare COVID-19 vaccines head-to-head
Published in Ahram Online on 02 - 10 - 2020

A major non-profit health emergencies group has set up a global laboratory network to assess data from potential COVID-19 vaccines, allowing scientists and drugmakers to compare them and speed up selection of the most effective shots.
Speaking to Reuters ahead of announcing the labs involved, Melanie Saville, director of vaccine R&D at the Coalition for Epidemic Preparedness Innovations (CEPI), said the idea was to “compare apples with apples” as drugmakers race to develop an effective shot to help control the COVID-19 pandemic.
The centralised network is the first of its kind to be set up in response to a pandemic.
In a network spanning Europe, Asia and North America, the labs will centralise analysis of samples from trials of COVID-19 candidates “as though vaccines are all being tested under one roof”, Saville said, aiming to minimise the risk of variation in results.
“When you start off (with developing potential new vaccines) especially with a new disease, everyone develops their own assays, they all use different protocols and different reagents - so while you get a readout, the ability to compare between different candidates is very difficult,” she told Reuters.
“By taking the centralised lab approach ... it will give us a chance to really make sure we are comparing apples with apples.”
The CEPI network will initially involve six labs, one each in Canada, Britain, Italy, the Netherlands, Bangladesh and India, Saville said.
Hundreds of potential COVID-19 vaccines are in various stages of development around the world, with shots developed in Russia and China already being deployed before full efficacy trials have been done, and front-runners from Pfizer PFE.N, Moderna MRNA.O and AstraZeneca AZN.L likely to have final-stage trial results before year-end.
Typically, the immunogenicity of potential vaccines is assessed in individual lab analyses, which aim to see whether biomarkers of immune response - such as antibodies and T-cell responses - are produced after clinical trial volunteers receive a dose, or doses, of the vaccine candidate.
But with more than 320 COVID-19 vaccine candidates in the works, Saville said, the many differences in data collection and evaluation methods are an issue.
As well as potential variations in markers of immunity, there are differences in how and where samples are collected, transported and stored - all of which can impact the quality and usefulness of the data produced, and make comparisons tricky.
And with a range of different vaccine technologies being explored - from viral vector vaccines to ones based on messenger RNA - standard evaluation of their true potential “becomes very complex”, she said.
“With hundreds of COVID-19 vaccines in development ... it's essential that we have a system that can reliably evaluate and compare the immune response of candidates currently undergoing testing,” she said.
By centralising the analysis in a lab network, much of what Saville called the “inter-laboratory variability” can be removed, allowing for head-to-head comparisons.
CEPI says all developers of potential COVID-19 vaccines can use the centralised lab network for free to assess their candidates against a common protocol. For now, the network will assess samples from early-stage vaccine candidate testing and first and second stage human trials, but CEPI said it hoped to expand its capacity to late stage (Phase III) trial data in the coming months.
Results produced by the network will be sent back to the developer, with neither CEPI nor the network owning the data.
CEPI itself is co-funding nine of the potential COVID-19 vaccines in development, including candidates from Moderna, AstraZeneca, Novavax NVAX.O and CureVac.


Clic here to read the story from its source.